CPT code 87802 denotes a laboratory immunoassay with direct optical (visual) observation to detect Group B Streptococcus. This test represents a point-of-care or laboratory-based rapid antigen/immune-detection method where a trained lab analyst performs the technical steps and reads results visually. Nationally, such tests are important for prenatal screening, intrapartum decision-making, and infection control measures because timely identification of Group B Streptococcus can influence management and prophylaxis.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the assay, typical sites of service, and which payers are commonly relevant for coverage and billing considerations. The publication outlines common modifiers and service-line context where available and flags areas where input data were not provided.

The report provides benchmarks and policy-relevant information where available, clarifies the service type and expected laboratory setting, and summarizes what billing staff and lab managers need to know about coding this test as CPT code 87802. Data not available in the input are noted where applicable.